Volume 17, Number 10—October 2011
Drug-Resistant Tuberculosis, KwaZulu-Natal, South Africa, 2001–2007
In Africa, incidence and prevalence of drug-resistant tuberculosis have been assumed to be low. However, investigation after a 2005 outbreak of extensively drug-resistant tuberculosis in KwaZulu-Natal Province, South Africa, found that the incidence rate for multidrug-resistant tuberculosis in KwaZulu-Natal was among the highest globally and would be higher if case-finding efforts were intensified.
In Africa, resistance to anti-tuberculosis (TB) drugs has been assumed to be low (1). In 2002, the national drug resistance survey showed rates of multidrug-resistant (MDR) TB in South Africa to be 3.0% among all TB cases, 1.6% among new cases, and 6.6% among previously treated cases (2). Surveys in other African countries have yielded MDR TB rates of <3% among all TB cases, low compared with >20% reported from former Soviet Union countries; however, MDR TB rates may not be as low as previously estimated (3–7). In response to a 2005 outbreak of extensively drug-resistant (XDR) TB in KwaZulu-Natal Province, South Africa (8), we conducted a retrospective study of the extent and distribution of drug-resistant TB in the province.
KwaZulu-Natal Province, population ≈10 million, contains 11 health districts with 68 hospitals in the public health sector. We analyzed existing laboratory records from the only 2 laboratories in the province that conducted culture and drug-sensitivity testing as part of routine clinical care. Since 2001, all samples from patients with MDR TB in the province were tested for susceptibility to second-line anti-TB drugs, except in 2004 and 2005, when 82% (1,143) and 55% (1,277) of samples, respectively, were not tested for fluoroquinolones. From 2006 on, all culture-positive cases in the province were tested for susceptibility to first-line and second-line anti-TB drugs. We reviewed laboratory results from 2001 through 2007 and determined the number of MDR TB and XDR TB cases for each district. To provide context for the 2005 XDR TB outbreak at the Church of Scotland Hospital (COSH) in KwaZulu-Natal Province (8), we also analyzed geographic distribution and time trends. Per definition, the number of MDR TB cases includes all XDR TB cases.
According to national guidelines, samples for culture should be collected from persons who are being initially examined for retreatment, those for whom treatment has failed, those whose sputum smear results are negative but who have clinical signs of TB and do not respond to antibacterial drug treatment (excluding TB treatment), and those suspected of having HIV and TB co-infection. Despite the guidelines, the intensity with which cultures were requested varied among districts. We compared culture-taking practices with prevalence of MDR TB per district during the same time frame. Culture-taking practices were derived from the number of patients for whom a culture was requested during 12 months after March 2006 and were analyzed per district and per 100,000 population. The proportion of identified MDR TB patients who received treatment with second-line anti-TB drugs was calculated by dividing the number of patients with laboratory-confirmed MDR TB by the number of patients admitted to King George V Hospital, the only TB hospital in the province that treated patients with MDR TB during the same period. (Detailed methods available from K.W. upon request.)
In 2007, a total of 2,799 cases (28 cases/100,000 population) of MDR TB were identified in KwaZulu-Natal. TB prevalence was 1,200 cases/100,000 population, and MDR accounted for 2.3% of reported cases in the province (http://arxiv.org/abs/1107.1800). XDR TB cases accounted for 9.6% of MDR TB cases (Table).
In 2007, MDR TB in the districts ranged from 10 (uThukela) to 57 (Umkhanyakude) cases per 100,000 population (Table). Incidence of MDR TB was highest for Umkhanyakude and Umzinyathi districts (location of COSH) (8). The proportion of MDR TB cases that were XDR TB cases also varied among districts (1.2%–53.1%). The 2 districts with the highest level of MDR TB (Umkhanyakude and Umzinyathi) had the highest and the lowest XDR TB prevalence, respectively (Table).
From 2001 to 2007, the level of MDR TB increased >10-fold, from 216 cases to 2,799 cases, respectively (Figure 1, panel A), and XDR TB increased from 6 cases to 270 cases, respectively (Figure 1, panel B). In part, the increase reflects increased sampling, which tripled between 2002 and 2007, from ≈40,000 to >120,000 samples tested each year. The variation in MDR TB prevalence between districts could be attributed to differences in culture-taking practice (Spearman correlation coefficient 0.82; p = 0.001) (Figure 2). XDR TB prevalence, expressed as proportion of MDR TB, was not affected by culture-taking practices because all positive cultures were tested for first-line and second-line anti-TB drugs.
XDR TB has been in KwaZulu-Natal Province since 2001 and was first identified in eThekwini. XDR TB increased rapidly in 2005 when the outbreak was identified, and 72% of all XDR TB cases in the province were at COSH (Figure 1, panel B). As a result of this outbreak, culture-taking practices in the rest of the province increased, and in 2007, the proportion of identified XDR TB cases in the province that were at COSH had decreased to 37%. Excluding Umzinyathi, an average of 6.5% of all MDR TB cases were also XDR TB.
Within 12 months after March 2006, only 32% (896) of 2,784 patients with laboratory-identified MDR TB had received treatment with second-line drugs. During 2005–2006, the average time between sputum collection and admission to King George V Hospital was 16 weeks. The delay reflects turnaround time for culture and sensitivity testing (4–6 weeks), delay in returning results to the referring health facility (not all sites have Internet access), tracing of patients, and hospital admission waiting time.
In 2007, South Africa ranked fourth among countries with the highest estimated number of MDR TB cases (9). Within South Africa, KwaZulu-Natal Province had the highest prevalence of drug-resistant TB and accounted for 38% (2,799) of 7,350 MDR TB cases and 50% (270) of 536 XDR TB cases in the country (10,11).
The reported MDR TB incidence rate per 100,000 population of KwaZulu-Natal is among the highest worldwide. Districts Umkhanyakude and Umzinyathi reported 57 and 48 cases/100,000 population, respectively, more than the highest previously reported estimate of 35 cases/100,000 population in Karakalpakstan, Uzbekistan (12). Because many patients never have a sample taken for culture and sensitivity testing, the identified level of MDR TB is an underestimate.
After the 2005 outbreak, COSH increased vigilance for drug resistance, and culture and sensitivity testing was conducted for all patients with suspected TB. If other clinics and hospitals in the province requested as many cultures as COSH, MDR TB in KwaZulu-Natal would amount to 68 cases/100,000 population, with an estimated 6,750 MDR TB cases and 526 XDR TB cases per year, 2–3× more than currently identified (Figure 2). Furthermore, the increase in XDR TB during 2006–2007 suggests ongoing transmission of XDR TB.
Study limitations include unavailability of data to assess trends in culture-taking practices, so we could not evaluate how culture-taking practices may have influenced the increase in reporting of MDR TB over time. Also unavailable were data for categorizing MDR TB cases as new or retreatment.
Our findings show that incidence rates of MDR TB in KwaZulu-Natal could be higher than previously estimated. Since 2007, steps have been taken to validate and implement rapid diagnostic tests for all TB patients in the province and to increase access to MDR TB treatment by increasing bed capacity and decentralizing the MDR TB treatment program. The challenge is ensuring that all patients with a new diagnosis of MDR TB have access to treatment. Similarly, ongoing transmission of TB must be reduced by implementation of sound infection control measures.
Dr Wallengren is the clinical core manager at KwaZulu-Natal Research Institute for TB and HIV at University of KwaZulu-Natal. Her research interests include TB, HIV, TB/HIV co-infection, epidemiology, and basic science.
We thank Adrian Koopman for advice on the spelling of Zulu district names.
The situational analysis of drug resistance in KwaZulu-Natal was prepared in response to a request from the Provincial Department of Health, KwaZulu Natal, with financial and technical support of the World Health Organization, and would not have been possible without the collaboration and involvement of National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital TB Laboratory, King George V Hospital, COSH, and the Department of Health. The World Health Organization supported study design; collection, analysis, and interpretation of data; and writing of the report. The decision to submit the article for publication was made by the World Health Organization and the South Africa Department of Health.
- World Health Organization. Anti-tuberculosis resistance in the world. Report no. 4. Geneva: The Organization; 2008.
- Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J. Survey of tuberculosis drug resistance in South Africa: final report. Pretoria (South Africa): Medical Research Council; 2004. p. 1–19 [cited 2011 May 7]. http://www.mrc.ac.za/operationaltb/reports.htm
- Institute of Medicine. Addressing the threat of drug-resistant tuberculosis. A realistic assessment of the challenge. In: Workshop summary, 2008 Nov 5; Washington. Washington: National Academies Press; 2009 [cited 2011 May 7]. http://www.ncbi.nlm.nih.gov/books/NBK45006/pdf/TOC.pdf
- Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis. 2008;14:1345–52.
- Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M. Challenges in estimating the total burden of drug-resistant tuberculosis. [Epub 2008 Mar 27]. Am J Respir Crit Care Med. 2008;177:1302–6.
- Nunes EA, De Capitani EM, Coelho E, Joaquim OA, Figueiredo IR, Cossa AM, Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002–2003. Int J Tuberc Lung Dis. 2005;9:494–500.
- Chirenda J, Menzies H, Moalosi G, Anisimova V, Radisowa K, Bachhuber M, The trend of resistance to anti-tuberculosis drugs in Botswana: results from the 4th national anti-tuberculosis drug resistance survey. In: Abstracts of the 40th Union World Conference on Lung Health; Cancun, Mexico; Dec 3–7, 2009. Int J Tuberc Lung Dis. 2009 (Suppl 1);13:S3 [cited 2011 May 7]. http://www.tbpolicy.ru/news/index.php?id=309&file=350
- Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–80.
- World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: report 2009. Publication no. WHO/HTM/TB/2009.411. Geneva: The Organization; 2009.
- Department of Health. Republic of South Africa. Statistical notes. Extremely drug resistant tuberculosis (XDR-TB) in South Africa. May 2008 [cited 2011 May 7]. http://www.doh.gov.za/facts/stats-notes/2008/xdr-tb.pdf
- Department of Health. Republic of South Africa. Tuberculosis strategic plan for South Africa, 2007–2011 [cited 2011 May 7]. http://www.doh.gov.za/docs/summit/tb.pdf
- Zager EM, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis. 2008;8:10.
Suggested citation for this article: Wallengren K, Scano F, Nunn P, Margot B, Buthelezi SSS, Williams B, et al. Drug-resistant tuberculosis, KwaZulu-Natal, South Africa, 2001–2007. Emerg Infect Dis [serial on the Internet]. 2011 Oct [date cited]. http://dx.doi.org/10.3201/eid1710.100952
- Page created: September 23, 2011
- Page last updated: September 23, 2011
- Page last reviewed: September 23, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)